(Q40897334)

English

The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

metabolic dysfunction–associated steatotic liver disease

1 reference

based on heuristic

inferred from title

10

object named as

Kazuhiko Koike

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

author name string

Kazuya Okushin

1

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Takeya Tsutsumi

2

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Kenichiro Enooku

3

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Hidetaka Fujinaga

4

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Akira Kado

5

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Junji Shibahara

6

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Masashi Fukayama

7

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Kyoji Moriya

8

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Hiroshi Yotsuyanagi

9

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

publication date

25 November 2015

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

51

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

808-818

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Bile acids as regulators of hepatic lipid and glucose metabolism

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Do therapeutic bile acids hit the sweet spot of glucose metabolism in NAFLD?

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

The Gordian Knot of dysbiosis, obesity and NAFLD.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Gut-liver axis in alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Bile acid levels are increased in the liver of patients with steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Plasma metabolomic profile in nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Genetic variations of bile salt transporters

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Autoimmune BSEP disease: disease recurrence after liver transplantation for progressive familial intrahepatic cholestasis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

The bile salt export pump: clinical and experimental aspects of genetic and acquired cholestatic liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Farnesoid X receptor is essential for normal glucose homeostasis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1148-Y

21 January 2018

The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26601667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/26601667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps

1 reference

https://pubmed.ncbi.nlm.nih.gov/26601667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00535-015-1148-Y

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40897334&oldid=1909880096"